RxDoctor Payments DataLook up a doctor →

Craig Buettner, MD

Family Medicine · Tuscaloosa, ALNPI 1134291263

Payments from drug & device makers

$16,960in general payments, 2019–2025

Across 1,216 payments — averaging $13.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$2K
  • Amgen$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$990
  • plus $9K from 54 others

What the payments were for

  • Food & beverage$16,85999%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk136$1,641
AbbVie(2 entities)151$1,579
Amgen95$1,409
AstraZeneca76$1,194
Pfizer72$1,061
Lilly USA, LLC69$990
GSK54$699
Optinose US, Inc.47$686
Takeda Pharmaceuticals U.S.A., Inc.34$594
Amarin Pharma, Inc.44$504
Bayer30$491
Corium, LLC35$476
Johnson & Johnson(2 entities)36$371
Boehringer Ingelheim23$328
Antares Pharma, Inc.19$327
Abbott15$298
Biohaven Pharmaceutical Holding Company Ltd.13$286
Eisai Inc.19$286
Merck23$264
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$264
Esperion Therapeutics, Inc.13$223
OPKO Pharmaceuticals, LLC28$214
Neos Therapeutics, LP10$162
Axsome Therapeutics, Inc.7$148
Novartis9$147
Otsuka America Pharmaceutical, Inc.9$132
Ferring Pharmaceuticals Inc.4$129
Sanofi-aventis U.S. LLC8$124
Aytu Biopharma, Inc.8$121
Teva Pharmaceuticals USA, Inc.7$113
Dexcom, Inc.6$103
Pacira Therapeutics, Inc.5$93
IBSA Pharma Inc.6$89
Phathom Pharmaceuticals, Inc.8$80
Jazz Pharmaceuticals Inc.4$76
Exact Sciences5$75
Kowa Pharmaceuticals America, Inc.5$69
Biohaven Pharmaceuticals, Inc.4$67
Arbor Pharmaceuticals, Inc.4$65
Tolmar, Inc.4$64
Neurocrine Biosciences, Inc.3$64
Sanofi Pasteur Inc.3$62
Currax Pharmaceuticals LLC4$62
Tris Pharma Inc4$62
Daiichi Sankyo Inc.3$61
Idorsia Pharmaceuticals US Inc4$57
Clarus Therapeutics Inc.4$54
Halozyme Inc2$54
Adlon Therapeutics L.p.3$47
Genentech USA, Inc.3$47
Supernus Pharmaceuticals, Inc.2$42
E.r. Squibb & Sons, L.L.C.2$33
Bioventus LLC2$32
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Astellas Pharma US Inc2$31
Xeris Pharmaceuticals, Inc.1$23
Alnylam Pharmaceuticals Inc.1$22
Collegium Pharmaceutical, Inc.1$21
Ultragenyx Pharmaceutical Inc.1$20
Noven Therapeutics, LLC1$19

How this compares

$16,960 in reported general payments places this provider in the 95th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$257,166
Medicare patients
392
Services billed
15,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$104,139
JardianceEmpagliflozin87$83,176
EliquisApixaban92$79,192
Repatha SureclickEvolocumab74$58,217
MounjaroTirzepatide50$53,249
FarxigaDapagliflozin Propanediol61$49,788
RybelsusSemaglutide31$31,645
Orphengesic ForteOrphenadrine/Aspirin/Caffeine11$31,233
Janumet XrSitagliptin Phos/Metformin Hcl40$30,793
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,077
BelsomraSuvorexant43$22,670
LinzessLinaclotide34$19,916
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$15,488
NexlizetBempedoic Acid/Ezetimibe17$14,799
TrulicityDulaglutide13$12,585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,641$135,783110 claims
Boehringer IngelheimJardiance$328$83,17687 claims
PfizerEliquis$1,061$79,19292 claims
Lilly USA, LLCMounjaro, Trulicity$990$65,83463 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,194$65,27780 claims
MerckJanumet Xr, Belsomra$264$53,46383 claims
GSKTrelegy Ellipta, Breo Ellipta$699$29,36139 claims
AbbVieLinzess, Synthroid$1,579$24,62583 claims
Esperion Therapeutics, Inc.Nexlizet$223$14,79917 claims
Johnson & JohnsonXarelto$371$10,93412 claims
Astellas Pharma US IncMyrbetriq$31$9,72513 claims
Kowa Pharmaceuticals America, Inc.Livalo$69$6,85514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →